Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia

References

• Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11:23–34.
   PubMed Web of Science ®Google Scholar
• Chen LS, Gandhi V. PIM kinases in AML. In: Andreeff M, ed. Targeted therapy of acute myeloid leukemia. New York, NY: Springer; 2015. p. 177–199.
   Google Scholar
• Aguirre E, Renner O, Narlik-Grassow M, et al. Genetic modeling of PIM proteins in cancer: proviral tagging and cooperation with oncogenes, tumor suppressor genes, and carcinogens. Front Oncol. 2014;4:109.
   PubMedGoogle Scholar
• Saurabh K, Scherzer MT, Shah PP, et al. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget. 2014;5:8503–8514.
   PubMed Web of Science ®Google Scholar
• Natarajan K, Xie Y, Burcu M, et al. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One. 2013;8:e74653.
   PubMed Web of Science ®Google Scholar
• Cen B, Xiong Y, Song JH, et al. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014;34:2517–2532.
   PubMed Web of Science ®Google Scholar
• Guo Z, Wang A, Zhang W, et al. PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. Blood. 2014;124:1777–1789.
   PubMed Web of Science ®Google Scholar
• Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev. 2014;34:136–159.
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Bearss D, et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009;114:4150–4157.
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Taverna P, et al. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011;118:693–702.
   PubMed Web of Science ®Google Scholar
• Yang Q, Chen LS, Neelapu SS, et al. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood. 2012;120:3491–3500.
   PubMed Web of Science ®Google Scholar
• Cervantes-Gomez F, Chen LS, Orlowski RZ, et al. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013;13:S317–S329.
   PubMedGoogle Scholar
• Natarajan K, Bhullar J, Shukla S, et al. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem Pharmacol. 2013;85:514–524.
   PubMed Web of Science ®Google Scholar
• Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123:905–913.
   PubMed Web of Science ®Google Scholar
• Kirschner AN, Wang J, van der Meer R, et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst. 2015;107:407.
   Google Scholar
• Keeton E, Palakurthi S, Alimzhanov M, et al. AZD1208, a novel, potent and selective pan PIM kinase inhibitor, demonstrates efficacy in models of acute myeloid leukemia blood. Blood (Suppl). 2011;118: Abstract 1540.
   Google Scholar
• Hospital MA, Green AS, Lacombe C, et al. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood. 2012;119:1791–1792.
   PubMed Web of Science ®Google Scholar
• Yang Q, Chen LS, Neelapu SS, et al. Combination of Pim kinase inhibitor, SGI-1776 with bendamustine in B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2013;2:S355–S362.
   Google Scholar
• Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16:1472–1487.
   PubMed Web of Science ®Google Scholar
• Dulyaninova NG, House RP, Betapudi V, et al. Myosin-IIA heavy-chain phosphorylation regulates the motility of MDA-MB-231 carcinoma cells. Mol Biol Cell. 2007;18:3144–3155.
   PubMed Web of Science ®Google Scholar
• Ruvinsky I, Sharon N, Lerer T, et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 2005;19:2199–2211.
   PubMed Web of Science ®Google Scholar
• Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177–189.
   PubMed Web of Science ®Google Scholar
• Zhang F, Beharry ZM, Harris TE, et al. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009;8:846–853.
   PubMed Web of Science ®Google Scholar
• Harada M, Benito J, Yamamoto S, et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015;6:37930–37947.
   PubMed Web of Science ®Google Scholar
• Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA. 2010;107:12469–12474.
   PubMed Web of Science ®Google Scholar
• Curi DA, Beauchamp EM, Blyth GT, et al. Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome Ph (+) -positive leukemias. Oncotarget. 2015;6:33206–33216.
   PubMed Web of Science ®Google Scholar
• Raninga PV, Di Trapani G, Tonissen KF. Cross talk between two antioxidant systems, thioredoxin and DJ-1: consequences for cancer. Oncoscience. 2014;1:95–110.
   PubMedGoogle Scholar
• He X, Zheng Z, Li J, et al. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Carcinogenesis. 2012;33:555–562.
   PubMed Web of Science ®Google Scholar
• Ismail IA, Kang HS, Lee HJ, et al. DJ-1 upregulates breast cancer cell invasion by repressing KLF17 expression. Br J Cancer. 2014;110:1298–1306.
   PubMed Web of Science ®Google Scholar
• Wang B, Qin H, Wang Y, et al. Effect of DJ-1 overexpression on the proliferation, apoptosis, invasion and migration of laryngeal squamous cell carcinoma SNU-46 cells through PI3K/AKT/mTOR. Oncol Rep. 2014;32:1108–1116.
   PubMed Web of Science ®Google Scholar
• Yuan LL, Green AS, Bertoli S, et al. Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia. Leukemia. 2014;28:293–301.
   PubMed Web of Science ®Google Scholar
• Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7:193–204.
   PubMed Web of Science ®Google Scholar
• Blanco-Aparicio C, Collazo AM, Oyarzabal J, et al. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett. 2011;300:145–153.
   PubMed Web of Science ®Google Scholar
• Pogacic V, Bullock AN, Fedorov O, et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 2007;67:6916–6924.
   PubMed Web of Science ®Google Scholar
• Yang C, Boyson CA, Di Liberto M, et al. CDK4/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity. Cancer Res. 2015;75:1838–1845.
   PubMed Web of Science ®Google Scholar
• Lin YW, Beharry ZM, Hill EG, et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010;115:824–833.
   PubMed Web of Science ®Google Scholar
• Meja K, Stengel C, Sellar R, et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol. 2014;167:69–79.
   PubMed Web of Science ®Google Scholar
• Garcia PD, Langowski JL, Wang Y, et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014;20:1834–1845.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Arowojolu O, Swinnen I, et al. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res. 2012;36:224–231.
   PubMed Web of Science ®Google Scholar
• Kelly KR, Espitia CM, Taverna P, et al. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol. 2011;156:129–132.
   PubMed Web of Science ®Google Scholar
• Beharry Z, Zemskova M, Mahajan S, et al. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009;8:1473–1483.
   PubMed Web of Science ®Google Scholar
• Haddach M, Michaux J, Schwaebe MK, et al. Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor. ACS Med Chem Lett. 2012;3:135–139.
   PubMed Web of Science ®Google Scholar
• Grundler R, Brault L, Gasser C, et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med. 2009;206:1957–1970.
   PubMed Web of Science ®Google Scholar
• Tao ZF, Hasvold LA, Leverson JD, et al. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. J Med Chem. 2009;52:6621–6636.
   PubMed Web of Science ®Google Scholar
• Fox CJ, Hammerman PS, Cinalli RM, et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 2003;17:1841–1854.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang J, Chen K, et al. eIF4B phosphorylation by Pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res. 2013;73:4898–4908.
   PubMed Web of Science ®Google Scholar
• Lu J, Zavorotinskaya T, Dai Y, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 2013;122:1610–1620.
   PubMed Web of Science ®Google Scholar